FindTrial
Sign In

Pharmaceutical Care for patients with Diabetes using Insulin

Pharmaceutical Care for patients with Diabetes mellitus treated with Insulin

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-8b27t9
Enrollment
Unknown
Registered
2019-10-16
Start date
2019-07-15
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

Experimental group: 50 patients with diabetes mellitus receiving conventional insulin treatment will receive a pharmacotherapeutic follow-up service. Patients will be followed for 9 months through a p
Other
N02.421.668

Sponsors

Universidade Estadual de Ponta Grossa
Lead Sponsor
Universidade Estadual de Maringá
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with diabetes mellitus treated with conventional insulin, attended by the Pharmacy of the Family Health Center of Fernandes Pinheiro; with cognitive ability; who agree to participate in the research by signing the Informed Consent Form.

Exclusion criteria

Exclusion criteria: Patients with cognitive difficulties who do not have a companion or caregiver, hindering the understanding of the pharmaceutical and study guidelines. Diabetes mellitus patients receiving insulin analogues or not receiving insulin treatment.

Design outcomes

Primary

MeasureTime frame
Expected Outcome 1. Improve treatment adherence by assessing the degree of agreement between the actual and estimated withdrawal intervals in days before and at the end of pharmacotherapeutic follow-up.;Expected Outcome 2. Improve glycemic control by reducing glycated hemoglobin from baseline. Data collected before the first intervention and at the 9th month, at the end of pharmacotherapeutic follow-up.;Expected Outcome 3. Improve patients' quality of life, according to the DQOL-Brazil-8 questionnaire, applied before and after pharmacotherapeutic follow-up.—

Secondary

MeasureTime frame
Improve glycemic control by reducing fasting blood glucose levels and self-monitoring of blood glucose. Data collected at all stages of pharmacotherapeutic follow-up.;Reduce problems related to pharmacotherapy, according to an instrument of the Ministry of Health. Data collected at all stages of pharmacotherapeutic follow-up.—

Countries

Brazil

Contacts

Public ContactGerusa Possagno

Universidade Estadual de Ponta Grossa

gerusach@hotmail.com+55-42-991317751

Outcome results

None listed

Source: REBEC (via WHO ICTRP)